Skip to main content
Home > Week in Review > Deals

Chronological Index of : Deals

 Current Issue
  • Caribou Biosciences, Novartis deal

    Caribou Biosciences Inc., Berkeley, Calif. Novartis AG (NYSE:NVS;SIX:NOVN), Basel, Switzerland Business: Gene/Cell therapy Caribou granted Novartis a non-exclusive, worldwide option to license the biotechs CRISPR-Cas9 …

    Published on 1/12/2015
  • Cytos, OnCore Biopharma deal

    Cytos Biotechnology AG (SIX:CYTN), Schlieren, Switzerland OnCore Biopharma Inc., Doylestown, Pa. Business: Infectious OnCore received exclusive, worldwide rights to use Cytos virus-like particle (VLP) platform to …

    Published on 1/12/2015
  • Daiichi Sankyo, Egalet deal

    Daiichi Sankyo Co. Ltd. (Tokyo:4568), Tokyo, Japan Egalet Corp. (NASDAQ:EGLT), Wayne, Pa. Business: Neurology Egalet purchased Sprix ketorolac tromethamine nasal spray from Daiichi Sankyos Luitpold Pharmaceuticals Inc. …

    Published on 1/12/2015
  • ex scientia, Sumitomo Dainippon deal

    ex scientia Ltd., Dundee, U.K. Sumitomo Dainippon Pharma Co. Ltd. (Tokyo:4506), Osaka, Japan Business: Neurology Sumitomo Dainippons Sunovion Pharmaceuticals Inc. subsidiary partnered with ex scientia to discover and …

    Published on 1/12/2015
  • GenSight Biologics, Pixium Vision, Fondation Voir et Entendre deal

    GenSight Biologics Inc., Paris, France Pixium Vision S.A. (Euronext:PIX), Paris, France Fondation Voir et Entendre, Paris, France Business: Ophthalmic GenSight, Pixium and public research organization Fondation Voir et …

    Published on 1/12/2015
  • Intellia Therapeutics, Novartis deal

    Intellia Therapeutics LLC, Cambridge, Mass. Novartis AG (NYSE:NVS;SIX:NOVN), Basel, Switzerland Business: Gene/Cell therapy Novartis received exclusive rights to Intellias gene-editing platform for ex vivo engineering …

    Published on 1/12/2015
  • Isis Pharmaceuticals, J&J deal

    Isis Pharmaceuticals Inc. (NASDAQ:ISIS), Carlsbad, Calif. Johnson & Johnson (NYSE:JNJ), New Brunswick, N.J. Business: Autoimmune Isis and Johnson & Johnsons Janssen Biotech Inc. unit partnered to discover and develop …

    Published on 1/12/2015
  • Kite Pharma, Amgen deal

    Kite Pharma Inc. (NASDAQ:KITE), Los Angeles, Calif. Amgen Inc. (NASDAQ:AMGN), Thousand Oaks, Calif. Business: Cancer Amgen will use Kites engineered autologous cell therapy (eACT) platform to develop chimeric antigen …

    Published on 1/12/2015
  • Merck, Kyorin deal

    Merck & Co. Inc. (NYSE:MRK), Whitehouse Station, N.J. Kyorin Pharmaceutical Co. Ltd. (Tokyo:4569), Tokyo, Japan Business: Autoimmune Mercks MSD K.K. subsidiary granted Kyorin co-marketing and co-promotion rights in …

    Published on 1/12/2015
  • Oncodesign, Isarna Therapeutics deal

    Oncodesign S.A. (Euronext:ALONC), Dijon, France Isarna Therapeutics GmbH, Munich, Germany Business: Cancer, Ophthalmic Oncodesign and Isarna extended through 2015 a February 2013 deal under which Oncodesign is …

    Published on 1/12/2015
  • Open Monoclonal Technology, HanAll deal

    Open Monoclonal Technology Inc., Palo Alto, Calif. HanAll Biopharma Co. Ltd. (KOSDAQ:009420), Seoul, South Korea Business: Antibodies OMT granted HanAll a license to use OmniRat, OmniMouse and OmniFlic platforms to …

    Published on 1/12/2015
  • Phenex, Gilead deal

    Phenex Pharmaceuticals AG, Ludwigshafen, Germany Gilead Sciences Inc. (NASDAQ:GILD), Foster City, Calif. Business: Hepatic Gilead acquired Phenexs farnesoid X receptor (FXR; NR1H4) program for an undisclosed upfront …

    Published on 1/12/2015
  • Thermo Fisher, Samsung Electronics deal

    Thermo Fisher Scientific Inc. (NYSE:TMO), Waltham, Mass. Samsung Electronics Co. Ltd. (LSE:SMSN;KSE:005930), Suwon, South Korea Business: Diagnostic Thermo Fisher and Samsung Electronics partnered to jointly develop and…

    Published on 1/12/2015
  • Vectura, J&J deal

    Vectura Group plc (LSE:VEC), Chippenham, U.K. Johnson & Johnson (NYSE:JNJ), New Brunswick, N.J. Business: Pulmonary, Inflammation Vectura granted Johnson & Johnsons Janssen Biotech Inc. unit an exclusive, worldwide …

    Published on 1/12/2015
  • AMAG Pharmaceuticals, Takeda deal

    AMAG Pharmaceuticals Inc. (NASDAQ:AMAG), Lexington, Mass. Takeda Pharmaceutical Co. Ltd. (Tokyo:4502), Osaka, Japan Business: Hematology The companies mutually terminated a 2010 deal granting the pharma exclusive rights…

    Published on 1/5/2015
  • Ariad, Otsuka Pharmaceutical deal

    Ariad Pharmaceuticals Inc. (NASDAQ:ARIA), Cambridge, Mass. Otsuka Pharmaceutical Co. Ltd., Tokyo, Japan Business: Cancer Otsuka received exclusive rights to commercialize and co-develop Iclusig ponatinib from Ariad in …

    Published on 1/5/2015
  • Ariosa Diagnostics, Roche deal

    Ariosa Diagnostics Inc., San Jose, Calif. Roche (SIX:ROG;OTCQX:RHHBY), Basel, Switzerland Business: Diagnostic Roche acquired diagnostics provider Ariosa for an undisclosed sum. The companies declined to disclose …

    Published on 1/5/2015
  • Baruch S. Blumberg Institute, OnCore Biopharma deal

    Baruch S. Blumberg Institute, Doylestown, Pa. OnCore Biopharma Inc., Doylestown, Pa. Business: Diagnostic, Infectious, Cancer The institute granted OnCore an exclusive, worldwide option to license products resulting …

    Published on 1/5/2015
  • Bina Technologies, Roche deal

    Bina Technologies Inc., Redwood City, Calif. Roche (SIX:ROG;OTCQX:RHHBY), Basel, Switzerland Business: Supply/Service Roche acquired genomic management solution company Bina for an undisclosed sum. Bina will join Roches…

    Published on 1/5/2015
  • Cardiome, Eddingpharm deal

    Cardiome Pharma Corp. (TSX:COM;NASDAQ:CRME), Vancouver, Beta.C. Eddingpharm Inc., Shanghai, China Business: Cardiovascular Cardiome granted Eddingpharm rights to develop and commercialize atrial fibrillation drug IV …

    Published on 1/5/2015
  • Cytokinetics, Astellas deal

    Cytokinetics Inc. (NASDAQ:CYTK), South San Francisco, Calif. Astellas Pharma Inc. (Tokyo:4503), Tokyo, Japan Business: Musculoskeletal The companies added the development of CK-2127107 for spinal muscular atrophy (SMA) …

    Published on 1/5/2015
  • GlaxoSmithKline, Roivant Sciences deal

    GlaxoSmithKline plc (LSE:GSK;NYSE:GSK), London, U.K. Roivant Sciences Ltd., New York, N.Y. Business: Neurology Roivants Roivant Neurosciences Ltd. subsidiary acquired SB742457 from GlaxoSmithKline. SB742457 has …

    Published on 1/5/2015
  • Immutep, Prima BioMed deal

    Immutep S.A., Orsay, France Prima BioMed Ltd. (ASX:PRR;NASDAQ:PBMD), Sydney, Australia Business: Cancer Prima BioMed completed its acquisition of Immutep for up to $25 million in cash, shares and warrants. Prima BioMed …

    Published on 1/5/2015
  • J&J, Eiger deal

    Johnson & Johnson (NYSE:JNJ), New Brunswick, N.J. Eiger Biopharmaceuticals Inc., San Carlos, Calif. Business: Infectious Eigers EB Pharma LLC subsidiary received exclusive rights to tipifarnib for virology and an …

    Published on 1/5/2015
  • MacroGenics, J&J deal

    MacroGenics Inc. (NASDAQ:MGNX), Rockville, Md. Johnson & Johnson (NYSE:JNJ), New Brunswick, N.J. Business: Cancer MacroGenics will grant Johnson & Johnsons Janssen Biotech Inc. unit exclusive, worldwide rights to …

    Published on 1/5/2015

< Previous   1  2  3  4  5  6  Next >
Subscribe Now
Free Trial

About BioCentury

Decision-shaping business intelligence for the global biotech and pharma industry since 1993